Europe · Markets & Finance · El Economista

Fresenius se hace con el control total de mAbxience por hasta 750 millones y completa la salida de Insud

Published by El Economista · Spain 9 h ago

Fresenius ha adquirido el 45% que no controlaba de mAbxience a Insud Pharma e Invim Corporativo por hasta 750 millones de euros. La operación supone la salida de Insud del capital…

Read the full article on El Economista Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.eleconomista.es)

Also worth reading

City A.M.

Legal 500 takes down site after accidentally publishing damning barrister reviews

This is Money

SMALL CAP MOVERS: A calmer week for Aim as bond rout piles pressure on blue-chips

Financial Times

My mortgage is a problem for the Fed, and for America

FXStreet

Swiss Franc emerges as a safe-haven as global bonds sell off

Proactive Investors

SMALL-CAP MOVERS: Warrants, wind-downs and a word from the FT. AIM's week of extremes

Reuters Markets